Kate Grillot

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index1.0kcitations23works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(22), Prostate Cancer Treatment and Research(18), Cancer, Lipids, and Metabolism(4), Advanced Breast Cancer Therapies(3), Computational Drug Discovery Methods(2)

Publications23 total

Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Methods from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 1 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 2 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 2 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Methods from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 4 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 4 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Data from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 5 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 5 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Data from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 1 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
eLife·2019· 7 citedOpen Access
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
eLife·2016· 117 citedOpen Access
Author response: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016· 5 citedOpen Access
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Journal of Medicinal Chemistry·2015· 244 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

James D. Joseph(23), John Sensintaffar(23), Beatrice Darimont(23), Richard A. Heyman(23), Eric D. Bischoff(22), Anna Aparicio(22), Céline Bonnefous(22), Peter J. Rix(22), Jeffrey H. Hager(22), Nicola J. Clegg(18), Michael E. Jung(18), Charles L. Sawyers(18), John Wongvipat(17), Chris Tran(17), Samedy Ouk(17), Yu Chen(17), Steven Dorow(17), Guangbin Yang(17), Teresa Wasielewska(17), Mark R. Herbert(17)